CINC Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-02-24 | 5AM Partners VI, LLC | 10 percent owner | 0 | U-Tender | D | 496,323 | 26.00 | 12,904,398.00 |
| 2023-02-24 | HEALY JAMES | director, 10 percent owner: | 19,608 | U-Tender | D | 9,803 | 26.00 | 254,878.00 |
| 2022-11-28 | HEALY JAMES | director, 10 percent owner: | 0 | S-Sale | D | 6,000 | 14.32 | 85,920.00 |
| 2023-02-24 | HEALY JAMES | director, 10 percent owner: | 0 | D-Return | D | 19,608 | 0.00 | 0.00 |
| 2023-02-24 | HEALY JAMES | director, 10 percent owner: | 0 | U-Tender | D | 6,073,949 | 26.00 | 157,922,674.00 |
| 2023-02-24 | Freeman Mason | officer: Chief Medical Officer | 40,000 | U-Tender | D | 2,494 | 26.00 | 64,844.00 |
| 2022-06-10 | Freeman Mason | officer: Chief Medical Officer | 2,494 | S-Sale | D | 6 | 15.21 | 91.26 |
| 2023-02-24 | Freeman Mason | officer: Chief Medical Officer | 0 | D-Return | D | 40,000 | 0.00 | 0.00 |
| 2023-02-24 | Freeman Mason | officer: Chief Medical Officer | 0 | U-Tender | D | 100 | 26.00 | 2,600.00 |
| 2023-02-24 | Freeman Mason | officer: Chief Medical Officer | 0 | D-Return | D | 30,178 | 0.92 | 27,764.00 |
| 2023-02-24 | Freeman Mason | officer: Chief Medical Officer | 0 | D-Return | D | 145,296 | 5.82 | 845,623.00 |
| 2023-02-24 | Freeman Mason | officer: Chief Medical Officer | 0 | D-Return | D | 120,380 | 7.62 | 917,296.00 |
| 2023-02-24 | Allison David D. | director | 0 | D-Return | D | 1,499 | 11.78 | 17,658.00 |
| 2023-02-24 | Allison David D. | director | 0 | D-Return | D | 29,411 | 13.60 | 399,990.00 |
| 2023-02-24 | Allison David D. | director | 0 | D-Return | D | 1,038 | 19.55 | 20,293.00 |
| 2023-02-24 | Allison David D. | director | 0 | D-Return | D | 881 | 20.20 | 17,796.00 |
| 2023-02-24 | Allison David D. | director | 0 | D-Return | D | 524 | 33.49 | 17,549.00 |
| 2023-02-24 | Ignelzi Troy A. | director | 0 | D-Return | D | 36,324 | 5.82 | 211,406.00 |
| 2023-02-24 | Ignelzi Troy A. | director | 0 | D-Return | D | 58,823 | 13.60 | 799,993.00 |
| 2023-02-24 | Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 0 | D-Return | D | 202,437 | 26.00 | 5,263,362.00 |
| 2023-02-24 | Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 0 | D-Return | D | 77,615 | 30.07 | 2,333,883.00 |
| 2023-02-24 | Lee June | director | 0 | D-Return | D | 47,954 | 16.00 | 767,264.00 |
| 2023-02-24 | Pearce Catherine | officer: Chief Operating Officer | 15,000 | U-Tender | D | 140,149 | 26.00 | 3,643,874.00 |
| 2023-02-24 | Pearce Catherine | officer: Chief Operating Officer | 0 | D-Return | D | 15,000 | 0.00 | 0.00 |
| 2023-02-24 | Pearce Catherine | officer: Chief Operating Officer | 0 | U-Tender | D | 1,500 | 26.00 | 39,000.00 |
| 2023-02-24 | Pearce Catherine | officer: Chief Operating Officer | 0 | D-Return | D | 110,136 | 2.55 | 280,847.00 |
| 2023-02-24 | Pearce Catherine | officer: Chief Operating Officer | 0 | D-Return | D | 13,236 | 0.00 | 0.00 |
| 2023-02-24 | THERO JOHN F | director | 0 | D-Return | D | 36,324 | 5.82 | 211,406.00 |
| 2023-02-24 | THERO JOHN F | director | 0 | D-Return | D | 58,823 | 13.60 | 799,993.00 |
| 2023-02-24 | de Garidel Marc | director, officer: Chief Executive Officer | 200,000 | U-Tender | D | 12,500 | 26.00 | 325,000.00 |
| 2023-02-24 | de Garidel Marc | director, officer: Chief Executive Officer | 0 | D-Return | D | 200,000 | 0.00 | 0.00 |
| 2023-02-24 | de Garidel Marc | director, officer: Chief Executive Officer | 0 | D-Return | D | 726,483 | 5.82 | 4,228,131.00 |
| 2023-02-24 | de Garidel Marc | director, officer: Chief Executive Officer | 0 | D-Return | D | 601,901 | 7.62 | 4,586,486.00 |
| 2023-01-26 | de Garidel Marc | director, officer: Chief Executive Officer | 212,500 | A-Award | A | 200,000 | 0.00 | 0.00 |
| 2023-01-26 | Pearce Catherine | officer: Chief Operating Officer | 155,149 | A-Award | A | 15,000 | 0.00 | 0.00 |
| 2023-01-26 | Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 202,437 | A-Award | A | 177,000 | 0.00 | 0.00 |
| 2023-01-26 | Freeman Mason | officer: Chief Medical Officer | 42,500 | A-Award | A | 40,000 | 0.00 | 0.00 |
| 2023-01-11 | Pearce Catherine | officer: Chief Operating Officer | 144,146 | M-Exempt | A | 13,235 | 0.00 | 0.00 |
| 2023-01-11 | Pearce Catherine | officer: Chief Operating Officer | 140,149 | F-InKind | D | 3,997 | 28.75 | 114,914.00 |
| 2023-01-11 | Pearce Catherine | officer: Chief Operating Officer | 13,236 | M-Exempt | D | 13,235 | 0.00 | 0.00 |
| 2023-01-06 | Allison David D. | director | 1,499 | A-Award | A | 1,499 | 8.34 | 12,502.00 |
| 2022-11-04 | Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 77,615 | A-Award | A | 77,615 | 0.00 | 0.00 |
| 2022-11-04 | Kalb Michael Wayne | officer: EVP & Chief Financial Officer | 25,437 | A-Award | A | 25,437 | 0.00 | 0.00 |
| 2022-11-04 | Kalb Michael Wayne | None | 0 | None | None | 0.00 | ||
| 2022-11-04 | Kalb Michael Wayne | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2022-10-07 | Allison David D. | director | 524 | A-Award | A | 524 | 23.85 | 12,497.00 |
| 2022-08-15 | 5AM Partners VI, LLC | 10 percent owner | 3,953,990 | P-Purchase | A | 112,667 | 30.00 | 3,380,010.00 |
| 2022-08-15 | 5AM Opportunities II, L.P. | director: | 487,333 | P-Purchase | A | 487,333 | 30.00 | 14,619,990.00 |
| 2022-08-15 | 5AM Partners VI, LLC | 10 percent owner | 487,333 | P-Purchase | A | 487,333 | 30.00 | 14,619,990.00 |
| 2022-08-15 | Sofinnova Capital IX | director: | 4,220,979 | P-Purchase | A | 133,333 | 30.00 | 3,999,990.00 |
| 2022-08-15 | Sofinnova Partners SAS | 10 percent owner | 4,220,979 | P-Purchase | A | 133,333 | 30.00 | 3,999,990.00 |
| 2022-08-11 | Sofinnova Venture Partners X, L.P. | 10 percent owner | 6,073,949 | P-Purchase | A | 500,000 | 30.00 | 15,000,000.00 |
| 2022-08-11 | Katabi Maha | director: | 6,073,949 | P-Purchase | A | 500,000 | 30.00 | 15,000,000.00 |
| 2022-08-11 | HEALY JAMES | director, 10 percent owner: | 6,073,949 | P-Purchase | A | 500,000 | 30.00 | 15,000,000.00 |
| 2022-08-11 | HEALY JAMES | director: | 6,000 | P-Purchase | A | 6,000 | 30.00 | 180,000.00 |
| 2022-08-11 | General Atlantic (SPV) GP, LLC | director: | 4,209,470 | P-Purchase | A | 83,000 | 30.00 | 2,490,000.00 |
| 2022-08-11 | GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 4,209,470 | P-Purchase | A | 83,000 | 30.00 | 2,490,000.00 |
| 2022-08-11 | GENERAL ATLANTIC, L.P. | 10 percent owner | 4,209,470 | P-Purchase | A | 83,000 | 30.00 | 2,490,000.00 |
| 2022-08-11 | General Atlantic GenPar (Lux) SCSp | director: | 4,209,470 | P-Purchase | A | 83,000 | 30.00 | 2,490,000.00 |
| 2022-08-05 | HEALY JAMES | director, 10 percent owner: | 29,411 | M-Exempt | A | 29,411 | 13.60 | 399,990.00 |
| 2022-08-05 | HEALY JAMES | director: | 0 | M-Exempt | D | 29,411 | 0.00 | 0.00 |
| 2022-08-05 | HEALY JAMES | director, 10 percent owner: | 0 | M-Exempt | D | 29,411 | 13.60 | 399,990.00 |
| 2022-07-08 | Allison David D. | director: | 881 | A-Award | A | 881 | 14.19 | 12,501.00 |
| 2022-04-08 | Allison David D. | director | 1,038 | A-Award | A | 1,038 | 19.55 | 20,293.00 |
| 2022-04-08 | Allison David D. | director: | 1,038 | A-Award | A | 1,038 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | director | 4,126,470 | P-Purchase | A | 1,700,000 | 16.00 | 27,200,000.00 |
| 2022-01-11 | GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 4,126,470 | P-Purchase | A | 1,700,000 | 16.00 | 27,200,000.00 |
| 2022-01-11 | GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | director | 2,426,470 | C-Conversion | A | 2,426,470 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 2,426,470 | C-Conversion | A | 2,426,470 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | director | 0 | C-Conversion | D | 8,250,000 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC GENPAR (BERMUDA), L.P. | 10 percent owner | 0 | C-Conversion | D | 8,250,000 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC, L.P. | director | 4,126,470 | P-Purchase | A | 1,700,000 | 16.00 | 27,200,000.00 |
| 2022-01-11 | GENERAL ATLANTIC, L.P. | 10 percent owner | 4,126,470 | P-Purchase | A | 1,700,000 | 16.00 | 27,200,000.00 |
| 2022-01-11 | GENERAL ATLANTIC, L.P. | director | 2,426,470 | C-Conversion | A | 2,426,470 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC, L.P. | 10 percent owner | 2,426,470 | C-Conversion | A | 2,426,470 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC, L.P. | director | 0 | C-Conversion | D | 8,250,000 | 0.00 | 0.00 |
| 2022-01-11 | GENERAL ATLANTIC, L.P. | 10 percent owner | 0 | C-Conversion | D | 8,250,000 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | 10 percent owner | 3,841,323 | P-Purchase | A | 157,500 | 16.00 | 2,520,000.00 |
| 2022-01-11 | 5AM Partners VI, LLC | director | 3,841,323 | P-Purchase | A | 157,500 | 16.00 | 2,520,000.00 |
| 2022-01-11 | 5AM Partners VI, LLC | director | 3,683,823 | C-Conversion | A | 3,683,823 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | 10 percent owner | 3,683,823 | C-Conversion | A | 3,683,823 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | director | 496,323 | P-Purchase | A | 312,500 | 16.00 | 5,000,000.00 |
| 2022-01-11 | 5AM Partners VI, LLC | 10 percent owner | 496,323 | P-Purchase | A | 312,500 | 16.00 | 5,000,000.00 |
| 2022-01-11 | 5AM Partners VI, LLC | 10 percent owner | 183,823 | C-Conversion | A | 183,823 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | director | 183,823 | C-Conversion | A | 183,823 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | director | 0 | C-Conversion | D | 625,000 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | director | 0 | C-Conversion | D | 9,999,999 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | 10 percent owner | 0 | C-Conversion | D | 9,999,999 | 0.00 | 0.00 |
| 2022-01-11 | 5AM Partners VI, LLC | 10 percent owner | 0 | C-Conversion | D | 625,000 | 0.00 | 0.00 |
| 2022-01-11 | CinRx Pharma, LLC | 10 percent owner | 3,630,103 | C-Conversion | A | 1,222,530 | 0.00 | 0.00 |
| 2022-01-11 | CinRx Pharma, LLC | 10 percent owner | 0 | C-Conversion | D | 2,142,856 | 0.00 | 0.00 |
| 2022-01-11 | CinRx Pharma, LLC | 10 percent owner | 0 | C-Conversion | D | 2,013,749 | 0.00 | 0.00 |
| 2022-01-11 | Sofinnova Venture Partners X, L.P. | 10 percent owner | 5,573,949 | P-Purchase | A | 325,000 | 16.00 | 5,200,000.00 |
| 2022-01-11 | Sofinnova Venture Partners X, L.P. | 10 percent owner | 5,248,949 | C-Conversion | A | 5,248,949 | 0.00 | 0.00 |
| 2022-01-11 | Sofinnova Venture Partners X, L.P. | 10 percent owner | 0 | C-Conversion | D | 13,571,428 | 0.00 | 0.00 |
| 2022-01-11 | Sofinnova Venture Partners X, L.P. | 10 percent owner | 0 | C-Conversion | D | 4,275,000 | 0.00 | 0.00 |
| 2022-01-11 | Sofinnova Partners SAS | 10 percent owner | 4,087,646 | P-Purchase | A | 220,000 | 16.00 | 3,520,000.00 |
| 2022-01-11 | Sofinnova Partners SAS | 10 percent owner | 3,867,646 | C-Conversion | A | 3,867,646 | 0.00 | 0.00 |
| 2022-01-11 | Sofinnova Partners SAS | 10 percent owner | 0 | C-Conversion | D | 9,999,999 | 0.00 | 0.00 |
| 2022-01-11 | Sofinnova Partners SAS | 10 percent owner | 0 | C-Conversion | D | 3,150,000 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
